Ankylosing Spondylitis Market Size, Trends, Growth Drivers, CAGR Status and Future Outlook
Ankylosing Spondylitis Market Size- By Drug Class, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Feb-2025 | Report ID: HLCA2551 | Pages: 1 - 251 | Formats*: |
| Category : Healthcare | |||
Ankylosing Spondylitis Market Introduction and Overview
According to SPER Market Research, the Global Ankylosing Spondylitis Market is estimated to reach USD 11.75 billion by 2034 with a CAGR of 6.66%.
The ankylosing spondylitis market is expected to grow further, owing to ongoing research, the release of novel medicines, and increased global awareness. Strategic agreements between pharmaceutical corporations and healthcare professionals are intended to increase treatment access and enhance patient outcomes. The global ankylosing spondylitis market is being driven primarily by an increase in the prevalence of the disease. However, the high cost of ankylosing spondylitis therapy and the side effects of medications used to treat ankylosing spondylitis slowed market growth throughout the projection period.
- January 2023: Amgen has announced the release of AMJEVITA, the first biosimilar of Humira, in the United States. Biosimilars are well-studied, FDA-approved therapies that have the potential to cut costs. Amgen is uniquely prepared to do so due to its track record of creating and producing biologics, as well as its decades of knowledge with inflammation.
- July 2023: Sandoz made a key announcement about developing Hyrimoz, a concentrated formulation, marking its entry into the field of immunology in the United States. Hyrimoz HCF has been approved to treat a variety of illnesses, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
By Drug Class: The TNF (Tumor Necrosis Factor) segment dominated the market. TNF inhibitors, which target tumor necrosis factors to treat autoimmune diseases including rheumatoid arthritis, are expected to see significant increase. This expansion is being driven by an increase in autoimmune disease diagnosis and breakthroughs in biological treatments. Overall, TNF-dominated factors, including the introduction of novel TNF inhibitors, are projected to play a significant role in determining market dynamics.
By Distribution Channel: The hospital pharmacy led the market and accounted for the largest revenue share. Furthermore, the rising incidence rate of the ailment, as well as an increase in the number of in-patients and out-patients, resulted in hospitalization, which fuelled the growth of the hospital pharmacy segment. One of the key factors driving hospital pharmacies' dominance is that specialist healthcare practitioners are required to administer and monitor the effects of TNF inhibitors, such as infusion therapy, making hospitals the ideal site for these treatments.
By Region: The North American ankylosing spondylitis market had the most revenue share in 2024. This growth is due to the availability of improved diagnostic techniques and high healthcare costs in North America. Furthermore, large pharmaceutical businesses in the region have contributed significantly to market growth.
Market Competitive Landscape:
The Global Ankylosing Spondylitis Market is highly consolidated. Some of the market players are AbbiVie, Inc, Amgen, Inc, Eli Lilly and Company, Izana Biosciences, Johnson and Johnson Services, Inc, Merck and Co., Inc, Novartis AG, Pfizer, In., UCB, Inc, Zydus Lifescience Ltd and others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Drug Class, By Distribution Channel. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, Middle East & Africa. |
| Companies Covered | AbbiVie, Inc, Amgen, Inc, Eli Lilly and Company, Izana Biosciences, Johnson and Johnson Services, Inc, Merck and Co., Inc, Novartis AG, Pfizer, Inc, UCB, Inc, Zydus Lifescience Ltd. and others. |
Key Topics Covered in the Report:
- Global Ankylosing Spondylitis Market Size (FY’2021-FY’2034)
- Overview of Global Ankylosing Spondylitis Market
- Segmentation of Global Ankylosing Spondylitis Market By Drug Class (Non-Steroidal Anti Inflammatory Drug, TNF Inhibitors)
- Segmentation of Global Ankylosing Spondylitis Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy)
- Statistical Snap of Global Ankylosing Spondylitis Market
- Expansion Analysis of Global Ankylosing Spondylitis Market
- Problems and Obstacles in Global Ankylosing Spondylitis Market
- Competitive Landscape in the Global Ankylosing Spondylitis Market
- Details on Current Investment in Global Ankylosing Spondylitis Market
- Competitive Analysis of Global Ankylosing Spondylitis Market
- Prominent Players in the Global Ankylosing Spondylitis Market
- SWOT Analysis of Global Ankylosing Spondylitis Market
- Global Ankylosing Spondylitis Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Ankylosing Spondylitis Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Ankylosing Spondylitis Market
7. Global Ankylosing Spondylitis Market, By Drug Class (USD Million) 2021-2034
7.1. Non-Steroidal Anti-inflammatory Drug (NSAID)7.2. TNF inhibitors
7.2.1. Humira7.2.2. Simponi7.2.3. Remicade7.2.4. Enbrel7.2.5. Cimzia
8. Global Ankylosing Spondylitis Market, By Distribution Channel (USD Million) 2021-2034
8.1. Hospital Pharmacy8.2. Retail Pharmacy
9. Global Ankylosing Spondylitis Market, (USD Million) 2021-2034
9.1. Global Ankylosing Spondylitis Market Size and Market Share
10. Global Ankylosing Spondylitis Market, By Region, (USD Million) 2021-2034
10.1. Asia-Pacific
10.1.1. Australia10.1.2. China10.1.3. India10.1.4. Japan10.1.5. South Korea10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France10.2.2. Germany10.2.3. Italy10.2.4. Spain10.2.5. United Kingdom10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia10.3.2. United Arab Emirates10.3.3. Qatar10.3.4. South Africa10.3.5. Egypt10.3.6. Morocco10.3.7. Nigeria10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada10.4.2. Mexico10.4.3. United States
10.5. Latin America
10.5.1. Argentina10.5.2. Brazil10.5.3. Rest of Latin America
11. Company Profile
11.1. AbbiVie, Inc
11.1.1. Company details11.1.2. Financial outlook11.1.3. Product summary11.1.4. Recent developments
11.2. Amgen, Inc
11.2.1. Company details11.2.2. Financial outlook11.2.3. Product summary11.2.4. Recent developments
11.3. Eli Lilly and Company
11.3.1. Company details11.3.2. Financial outlook11.3.3. Product summary11.3.4. Recent developments
11.4. Izana Biosciences
11.4.1. Company details11.4.2. Financial outlook11.4.3. Product summary11.4.4. Recent developments
11.5. Johnson and Johnson Services, Inc
11.5.1. Company details11.5.2. Financial outlook11.5.3. Product summary11.5.4. Recent developments
11.6. Merck and Co., Inc
11.6.1. Company details11.6.2. Financial outlook11.6.3. Product summary11.6.4. Recent developments
11.7. Novartis AG
11.7.1. Company details11.7.2. Financial outlook11.7.3. Product summary11.7.4. Recent developments
11.8. Pfizer, Inc
11.8.1. Company details11.8.2. Financial outlook11.8.3. Product summary11.8.4. Recent developments
11.9. UCB, Inc
11.9.1. Company details11.9.2. Financial outlook11.9.3. Product summary11.9.4. Recent developments
11.10. Zydus Lifescience Ltd
11.10.1. Company details11.10.2. Financial outlook11.10.3. Product summary11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Ankylosing Spondylitis Market is projected to reach USD 11.75 billion by 2034, growing at a CAGR of 6.66% during the forecast period.
Ankylosing Spondylitis Market grew in Market size from 2025. The Market is expected to reach USD 11.75 billion by 2034, at a CAGR of 6.66% during the forecast period.
Ankylosing Spondylitis Market CAGR of 6.66% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Ankylosing Spondylitis Market size is USD 11.75 billion from 2025 to 2034.
Ankylosing Spondylitis Market is covered By Drug Class, By Distribution Channel.
The North America is anticipated to have the highest Market share in the Ankylosing Spondylitis Market.
The key players in the Market include Companies Covered AbbiVie, Inc, Amgen, Inc, Eli Lilly and Company, Izana Biosciences, Johnson and Johnson Services, Inc, Merck and Co., Inc, Novartis AG, Pfizer, Inc, UCB, Inc, Zydus Lifescience Ltd. and others.
The global ankylosing spondylitis market is being driven primarily by an increase in the prevalence of the disease. However, the high cost of ankylosing spondylitis therapy and the side effects of medications used to treat ankylosing spondylitis slowed market growth throughout the projection period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
